Knight Therapeutics Closes US$38.5 million Loan with IFC
MONTREAL, Dec. 23, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the International Finance Corporation (“IFC”), a member of the World Bank Group focused on the private sector in emerging […]
News
Knight Announces Relaunch of AKYNZEO® in Canada
MONTREAL, Dec. 01, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO® (netupitant/palonosetron capsules) in Canada. Knight and Helsinn Healthcare SA (“Helsinn”) entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO® in Canada, […]
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Knight Therapeutics Reports Third Quarter 2022 Results
Record revenues and adjusted EBITDA for the first nine months of 2022 MONTREAL, Nov. 10, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2022. All currency amounts are in thousands except for share and […]
Knight to Present at Stifel Healthcare Conference
MONTREAL, Nov. 09, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the upcoming Stifel Healthcare Conference on Tuesday, November 15, 2022, at 1:15 pm ET at the […]
Notice of Knight Therapeutics’ Third Quarter 2022 Results Conference Call
MONTREAL, Nov. 03, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2022 financial results on Thursday, November 10, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
MONTREAL, Oct. 06, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory […]
Knight Therapeutics Inc. places No. 22 on The Globe and Mail’s fourth-annual ranking of Canada’s Top Growing Companies
MONTREAL, Sept. 23, 2022 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 22 on the 2022 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 1,850%. “We are […]
Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil
MONTREAL, Aug. 15, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has assumed full commercial activities and is re-launching Exelon® (rivastigmine) in Brazil following successful transfer of the marketing authorization. On May 26, 2021, Knight completed the acquisition of the […]
